TD Cowen Initiates Coverage On Halozyme Therapeutics with Outperform Rating, Announces Price Target of $54
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Brendan Smith initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with an Outperform rating and a price target of $54.
February 29, 2024 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen initiated coverage on Halozyme Therapeutics with an Outperform rating and set a price target of $54.
The initiation of coverage by TD Cowen with an Outperform rating and a high price target suggests a positive outlook for Halozyme Therapeutics' stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100